Latest Europe News

Energy One (ASX:EOL) reported a strong FY26 with 14% revenue growth and 38% profit rise, announcing a transformative $99.8 million all-scrip acquisition of Gas Management Services Limited (GMSL) that will deepen its European footprint and bring Fluxys onboard as a major shareholder.

Victory Metals (ASX: VTM) has delivered a robust Pre-Feasibility Study for its North Stanmore rare earth project, confirming a 47 Mt Probable Ore Reserve and strong economics underpinned by low capital intensity and a high-grade mineral resource.

Pro Medicus delivered a robust FY26 with 28% underlying revenue growth, a surge in new contract wins worth $407 million, and a 25% increase in fully franked dividends, underpinned by strong AI product development and rapid implementations.

EML Payments reported a 6% revenue decline and an 18% drop in underlying EBITDA for FY26, completing a major restructuring and advancing its Arlo technology platform. The company projects FY27 EBITDA between $50 million and $54 million, with a strong new program pipeline and strategic investments underpinning growth.

Yugo Metals continues to hit significant gold grades in its maiden drilling at the Erak Prospect, with mineralisation open in multiple directions and further drilling underway.

CSL Limited’s FY2026 results reveal modest revenue growth offset by a multibillion-dollar statutory loss driven by restructuring and impairments, alongside a maintained dividend and a strategic focus on sustainable growth.

Scott Technology has locked in NZ$20 million worth of new Materials Handling & Logistics contracts across North America and Europe, reinforcing its Destination 2030 growth strategy and building on strong FY26 momentum.

Mesoblast has treated 350 patients in its pivotal Phase 3 trial for rexlemestrocel-L, targeting chronic low back pain linked to degenerative disc disease, setting the stage for top-line results in mid-2027.

Dimerix has secured full sponsorship of the US Investigational New Drug application for its Phase 2-ready kidney drug DMX-652, setting the stage for a clinical trial targeting acute kidney injury in late 2026.

OncoSil Medical has won FDA Humanitarian Device Exemption approval for its OncoSil™ device to treat distal cholangiocarcinoma, opening a US market estimated at A$80 million annually.

Temas Resources posted a CAD 2.63 million loss for H1 2026, driven by ramped-up exploration and RCL technology development, while securing $1.5 million in fresh funding and signing initial RCL licensing contracts.

Laramide Resources has secured strategic uranium exploration licences in Sweden’s Hotagen and Arjeplog-Arvidsjaur provinces, capitalising on the country’s recent policy reversal to permit uranium mining.